A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels

Canadian Journal of Gastroenterology and Hepatology

Volumn 29, Issue 1, 2015, Pages 35-40

  Huang, Vivian Wai Mei ^a   Dhami, Neil ^a   Fedorak, Darryl ^a   Prosser, Connie ^a   Shalapay, Carol ^a   Kroeker, Karen Ivy ^a   Halloran, Brendan Phillip ^a   Dieleman, Levinus Albert ^a   Fedorak, Richard Neil ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adverse events; Infliximab; Infusion reaction; Trough level

Indexed keywords

INFLIXIMAB; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; CORRELATION ANALYSIS; CROHN DISEASE; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; SKIN MANIFESTATION; ULCERATIVE COLITIS; ADVERSE EFFECTS; BLOOD; COLITIS, ULCERATIVE; DRUG ERUPTION; DRUG MONITORING; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DRUG ERUPTIONS; DRUG MONITORING; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; INFUSIONS, INTRAVENOUS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84922459197     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2015/428702     Document Type: Article

References (33)

1. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immunemediated inflamamtion in inflammatory bowel disease patients receiving anti-TNF-a agents. Autoimmun Rev 2014;13:15-9.
2. Niess JH, Danese S. Anti-TNF and skin inflammation in IBD: A new paradox in gastroenterology? Gut 2014;63:533-5.
3. Moran GW, Lim AW, Bailey JL et al. Dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:1002-24.
4. Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. J Crohns Colitis 2013:1-11.
5. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
6. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010;40:233-40.
7. Hernández MV, Sanmartí R, Cañete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumour necrosis factor antagonists. Study based on the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases. Arthritis Care Res 2013;65:2024-31.
8. Mayer L, Young Y. Infusion reactions and their management. Gastroenterol Clin North Am 2006;35:857-66.
9. Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2008;28:221-7.
10. Yanai H, Shuster D, Calabrese E, Mlynarsky L, Tumuluri S, Cohen RD. The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. Inflamm Bowel Dis 2013:19:2778-86.
11. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol 2012;39:481-92.
12. Rahier JF, Buche S, Biroulet LP, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010;8:1048-55.
13. Verma HD, Scherl EJ, Jacob VE, Bosworth BP. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab. J Dig Dis 2011;12:379-83.
14. Denadai R, Teixeira FV, Saad-Hossne R. The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: Should biological therapy be suspended? Arq Gastroenterol 2012;49:172-6.
15. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009;124:1259-66.
16. Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC. Allergy to monoclonal antibodies: Cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol 2012;8:43-54.
17. Casteele NV, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108:962-71.
18. Matucci A, Pratesi S, Petroni G, et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 2013;43:659-64.
19. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: From pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol 2011;11:262-8.
20. Vultaggio A, Matucci A, Nencini F, Pratesi S, Maggi E. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. Intern Emerg Med 2011;7:77-9.
21. Roux CH, Brocq O, Leccia N, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: A class effect? J Rheumatol 2007;34:434-7.
22. De Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31.
23. Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-a therapy for inflammatory bowel disease: A systematic literature review based on 222 cases. J Crohns Colitis 2013;7:517-24.
24. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibodyinduced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014;63:567-77.
25. Kip KE, Swoger JM, Grandinetti LM, Barrie AM III, Greer JB, Regueiro MD. Tumor necrosis factor-{alpha} antagonist-associated psoriasis in inflammatory diseases. Inflamm Bowel Dis 2013;19:1164-72.
26. Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor. J Am Acad Dermatol 2012;67:e179-e185.
27. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatol Treat 2009;20:100-8.
28. Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases. J Crohns Colitis 2012;6:518-23.
29. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011;34:1318-27.
30. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
31. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol 2003;98:1315-24.
32. Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: Aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:51-8.
33. O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease. Inflamm Bowel Dis 2014;20:1-6.